OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
October 25, 2006
Merck's Januvia has a head start, but Novartis isn't sitting idle.
Emerging countries are expected to drive pharma's earnings next year.
After winning a bidding war for Pliva, the well-positioned generic maker is giving pharma reason to worry.